Novo, Novartis drugs cut heart-risk markers but not cardiovascular events

The FDA is requiring warnings on GLP-1 drugs, including Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Mounjaro, due to a potential link to a rare eye condition, NAION. The FDA's decision follows an analysis of clinical trials and patient data. Citi analysts expect limited impact on drug usage despite the new warning.

The FDA ordered warnings for GLP-1 drugs, including Eli Lilly's Mounjaro, Zepbound, and Novo Nordisk's Ozempic, Wegovy, about rare vision-loss risks. Despite this, shares of Eli Lilly and Novo Nordisk rose 4.3% and 2.7% respectively. Lilly's Q3 earnings showed strong sales of $10.7B for Mounjaro and $5.4B for Zepbound, accounting for two-thirds of its revenue. Novo raised its full-year outlook but expects flat sales growth.

Novartis' pelacarsen and Novo Nordisk's ziltivekimab failed to reduce cardiovascular events despite targeting Lp(a) and inflammation. Novartis' drug, tested on 8,300 patients, showed no benefit in preventing heart attacks or strokes. Novo Nordisk's trial on 6,300 patients also showed no reduction in major cardiovascular events. Both companies presented findings at the American Heart Association meeting.

Novo Nordisk (NOVO B) received an FDA warning about a rare vision loss risk associated with its GLP-1 drugs, including Wegovy. The FDA is requiring label updates based on clinical trials and real-world reports. Novo Nordisk has a market cap of DKK1.2 trillion and focuses on treatments for chronic conditions. The warning may impact the company's margins and legal exposure, but it does not alter the core growth prospects for its GLP-1 portfolio.

The FDA is mandating new safety warnings for GLP-1 drugs, including Wegovy and Zepbound, due to a potential link to a rare eye condition, NAION, which can cause sudden vision loss. The FDA's decision follows a review of clinical trials and real-world data. Novo Nordisk and Eli Lilly, makers of these drugs, have been contacted for comment.

The FDA ordered manufacturers of GLP-1 drugs, including Ozempic, Wegovy, Mounjaro, and Zepbound, to add warnings about rare optic nerve damage risk. The warning follows a review of clinical trials and studies showing a higher incidence of non-arteritic anterior ischemic optic neuropathy (NAION) in patients using these drugs. Novo Nordisk and Eli Lilly, manufacturers of these drugs, have responded to the FDA's announcement.